glp-1 roe Mechanisms by which agonists may exert beneficial effects on the Everything You Need to Know

B., Gonzalez, M

As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)

Common incretin-related effects discussed in the broader GLP-1 and metabolic drug class may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, or abdominal discomfort, but trial observations do not establish safe personal use of a research peptide

Investments are significant in the region, driving rapid product launches, clinical trials for new indications, and early adoption of innovative GLP-1 formulations, including oral and long-acting injectables